Suspension of trading

NeuBase Therapeutics, Inc. Stock

O7P

US64132K2015

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 02:03:16 2024-05-13 EDT			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.14M 1.06M 966K 1.82M 123M 1.83M 12.83M 4.99M 62.81M 4.8M 4.69M 202M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.14M 1.06M 966K 1.82M 123M 1.83M 12.83M 4.99M 62.81M 4.8M 4.69M 202M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news: NeuBase Therapeutics, Inc.

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
24-06-27	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
24-05-28	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	2021-10-31

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	2025-01-03

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-50.64%	1.39M
WUXI APPTEC CO., LTD.	+4.16%	+3.42%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.81%	+19.75%	+78.12%	57.39B
LONZA GROUP AG	+1.63%	-1.61%	+3.83%	+36.89%	47.64B
REVOLUTION MEDICINES, INC.	+0.50%	+2.94%	+344.62%	+722.17%	44.29B
IQVIA HOLDINGS INC.	+3.05%	-1.80%	+28.78%	+34.51%	42.5B
BEONE MEDICINES AG	+1.00%	-1.46%	+5.17%	+111.90%	40.71B
CELLTRION, INC.	-0.54%	+2.41%	+9.31%	+58.85%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+3.75%	+31.34%	+29.14%	28.53B
BIONTECH SE	+0.76%	-1.45%	-7.44%	-11.12%	24.34B
Average	+1.12%	-0.54%	+48.47%	+110.40%	39.05B
Weighted average by Cap.	+1.55%	-0.41%	+58.06%	+137.29%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company